Sophie Viaud
YOU?
Author Swipe
View article: 305 CD38 engineering enables CAR-T and anti-CD38 monoclonal antibody combination therapy
305 CD38 engineering enables CAR-T and anti-CD38 monoclonal antibody combination therapy Open
View article: 284 Rapid manufacturing reveals memory cell-like CD4 CAR T cells as key drivers of sustained anti-tumor activity
284 Rapid manufacturing reveals memory cell-like CD4 CAR T cells as key drivers of sustained anti-tumor activity Open
View article: 266 Functional and genomics analysis on product identifies key features driving resistance to CAR T-cell therapy, including dysfunctional GATA3+ CD8 T cells
266 Functional and genomics analysis on product identifies key features driving resistance to CAR T-cell therapy, including dysfunctional GATA3+ CD8 T cells Open
View article: 249 CD3ε enhances CAR-T fitness and persistence by promoting the survival of effector memory T cells
249 CD3ε enhances CAR-T fitness and persistence by promoting the survival of effector memory T cells Open
View article: 285 A non-viral engineering platform for rapid CAR T cell manufacturing and delivery of complex genetic payloads
285 A non-viral engineering platform for rapid CAR T cell manufacturing and delivery of complex genetic payloads Open
View article: Supplementary Figure Legends 1-4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Figure Legends 1-4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 98K
View article: Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands Open
Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
View article: Supplementary Table 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Table 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 297K, Differentially expressed genes between Kit+ and Kit- samples, FC >2, p-value <0.05, difference of mean > 100
View article: Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer Open
Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
View article: Supplementary Figure 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Figure 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 105K, IL-18 does not promote the proliferation of Kit+ NK cells in vivo
View article: Data from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Data from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
During cancer development, a number of regulatory cell subsets and immunosuppressive cytokines subvert adaptive immune responses. Although it has been shown that tumor-derived interleukin (IL)-18 participates in the PD-1–dependent tumor pr…
View article: Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer Open
Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
View article: Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer Open
Supplementary Figure 2 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
View article: Supplementary Table 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Table 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 307K, Differentially expressed genes between Kit+ and Kit- samples, coding for annotated genes, FC >2, p-value <0.05, difference of mean > 100
View article: Data from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Data from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients Open
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and ca…
View article: Supplementary Table 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Table 2 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 307K, Differentially expressed genes between Kit+ and Kit- samples, coding for annotated genes, FC >2, p-value <0.05, difference of mean > 100
View article: Supplementary Figure Legends 1-4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Figure Legends 1-4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 98K
View article: Data from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Data from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer Open
Immunosuppressive cytokines subvert innate and adaptive immune responses during cancer progression. The inflammatory cytokine interleukin-18 (IL-18) is known to accumulate in cancer patients, but its pathophysiological role remains unclear…
View article: Supplementary Table 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Table 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 297K, Differentially expressed genes between Kit+ and Kit- samples, FC >2, p-value <0.05, difference of mean > 100
View article: Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients Open
Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
View article: Data from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Data from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients Open
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and ca…
View article: Supplementary Figure Legends 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Supplementary Figure Legends 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands Open
Supplementary Figure Legends 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
View article: Supplementary Figure 3 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Figure 3 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 119K, Kit signaling is not involved in Kit+ NK cell differentiation and survival
View article: Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients Open
Supplementary Figure 2 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
View article: Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands Open
Supplementary Figures 1-6 from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
View article: Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer Open
Supplementary Figure 1 from IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
View article: Data from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Data from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands Open
Many cancer cells express Toll-like receptors (TLR) that offer possible therapeutic targets. Polyadenylic-polyuridylic acid [poly(A:U)] is an agonist of the Toll-like receptor TLR3 that displays anticancer properties. In this study, we ill…
View article: Supplementary Figure 1 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Supplementary Figure 1 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients Open
Supplementary Figure 1 from Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
View article: Supplementary Figure 4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Supplementary Figure 4 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells Open
PDF file - 111K, Phenotypic features of Kit+ NK cells compared with Kit- NK cells
View article: Data from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Data from Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands Open
Many cancer cells express Toll-like receptors (TLR) that offer possible therapeutic targets. Polyadenylic-polyuridylic acid [poly(A:U)] is an agonist of the Toll-like receptor TLR3 that displays anticancer properties. In this study, we ill…